Screener
Tango Therapeutics TNGX EPS (Diluted)
Discontinued — last reported Q1 '26
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss before income taxes | (45,513) | (39,842) |
| Provision for income taxes | (1) | (34) |
| Net loss | $(45,514) | $(39,876) |
| Net loss per common share – basic and diluted | $(0.32) | $(0.36) |
| Weighted average number of common shares outstanding – basic and diluted | 143,576,292 | 110,301,256 |
| Net loss | $(45,514) | $(39,876) |
| Other comprehensive income (loss): | ||
| Unrealized (loss) gain on marketable securities | (339) | (142) |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's EPS (diluted)?
- Tango Therapeutics (TNGX) reported EPS (diluted) of -$0.32 in Q1 2026.
- How has Tango Therapeutics's EPS (diluted) changed year-over-year?
- Tango Therapeutics's EPS (diluted) increased by 11.1% year-over-year, from -$0.36 to -$0.32.
- What is the long-term trend for Tango Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Tango Therapeutics's EPS (diluted) has grown at a -1.1% compound annual growth rate (CAGR), from -$0.92 to -$0.88.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Tango Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude